Bruker Corporation (BRKR) is Reiterated by Mizuho to Neutral, Lowers Price Target to $ 23

Bruker Corporation (BRKR) was Reiterated by Mizuho to “Neutral” while Lowering the Price Target of the company shares to $ 23 from a previous price target of $28 . Mizuho advised their investors in a research report released on Aug 3, 2016.

Many Wall Street Analysts have commented on Bruker Corporation. Bruker Corporation was Downgraded by Wells Fargo to ” Market Perform” on Aug 3, 2016. Shares were Reiterated by Cantor Fitzgerald on Aug 3, 2016 to “Buy” and Lowered the Price Target to $ 28 from a previous price target of $34 .

On the company’s financial health, Bruker Corporation reported $0.20 EPS for the quarter, based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus estimate of $0.20. The company had revenue of $371.70 million for the quarter, compared to analysts expectations of $410.42 million. The company’s revenue was down -6.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.19 EPS.

Bruker Corporation closed down -0.09 points or -0.36% at $24.72 with 16,58,455 shares getting traded on Tusday. Post opening the session at $24.73, the shares hit an intraday low of $24.31 and an intraday high of $24.9025 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jun 15, 2016, Frank H Laukien (CEO) purchased 4,174 shares at $23.95 per share price. According to the SEC, on May 11, 2016, Brenda J Furlong (director) sold 22,600 shares at $27.43 per share price. On May 11, 2016, Wolf-dieter Emmerich (director) sold 21,000 shares at $27.35 per share price, according to the Form-4 filing with the securities and exchange commission.

Bruker Corporation is a designer and manufacturer of life science and materials research systems and associated products that address the needs of a range of customers in life science research pharmaceuticals applied markets nanotechnology cell biology clinical research microbiology and in-vitro diagnostics. The Company operates through two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI is organized into three operating segments: the Bruker BioSpin Group the Bruker CALID Group and the Bruker Nano Group. BEST designs manufactures and distributes superconducting materials. The company maintains technical and manufacturing centers in Europe and North America and it has sales offices located throughout the world.

Bruker Corporation

Leave a Reply

Bruker Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bruker Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.